Ciliatech News & Updates

Follow Ciliatech’s past history and latest exciting developments via the news stories below.

INTERCIL® branded image

Study will evaluate INTERCIL in patients with primary open-angle glaucoma as Ciliatech advances US clinical development program Epagny Metz-Tessy, France, September 8, 2026 – Ciliatech, a medical technology company developing surgical solutions for glaucoma, today announces approval by the US Food and Drug Administration (FDA) of the company’s Investigational Device

Ciliatech is pleased to announce the publication of 24-month clinical data for INTERCIL® in Ophthalmology and Therapy. The publication, titled “A Prospective Evaluation of the 2-Year Efficacy and Safety of INTERCIL®: A Uveal Spacer for Open-Angle Glaucoma,” reports outcomes from the SAFARI 3 study evaluating our glaucoma implant, the INTERCIL®

Saima Khokhar

Ciliatech are delighted to announce the appointment of Saima Khokhar as International Scientific & Medical Affairs Manager, joining the company on a full-time basis to support its growing international medical and scientific affairs function. In her new role, Saima will work closely with Ciliatech’s clinical, scientific and commercial teams to

Tristan Kaloo

Ciliatech are delighted to announce the appointment of Tristan Kaloo as Sales Director, joining the company to lead its commercial organisation during an exciting period of international growth and reporting directly to Sahil Syed, VP Sales & Marketing. In his new role, Tristan will lead Ciliatech’s European sales strategy, support

Serena Weinrich

Ciliatech are delighted to announce the appointment of Serena Weinrich as Surgical Glaucoma Specialist, Southern Germany, joining the company’s commercial team in Germany and reporting to Gabriele Grubert. In her new role, Serena will work closely with surgeons, hospitals and commercial partners across Southern Germany, providing clinical support while contributing

Daniela Muller

Ciliatech are delighted to announce the appointment of Daniela Müller as Senior Surgical Specialist, joining the company’s commercial team in Germany and reporting to Gabriele Grubert. In her new role, Daniela will support the continued growth of Ciliatech’s commercial activities across Germany, working closely with surgeons, hospitals and commercial partners

Javier Rodriguez

Ciliatech are delighted to announce the appointment of Javier Rodríguez as International Surgical Trainer, joining the company on a full-time basis to support its expanding surgical education activities across Europe. In his new role, Javier will provide surgical training for both new surgeons and new members of the commercial team,

Gloria Castillo

Ciliatech are delighted to announce the appointment of Gloria Castillo as Sales Support Assistant, joining the company on a full-time permanent basis and reporting directly to Sahil Syed, VP Sales & Marketing. In her new role, Gloria will support Ciliatech’s growing commercial organisation from the company’s regional office in Lyon,

Mandy Robinson Profile Pic

Ciliatech are delighted to announce the appointment of Mandy Robinson as Senior Surgical Glaucoma Sales Specialist, UK & Ireland, joining the company to strengthen its commercial organisation and reporting directly to Sahil Syed, VP Sales & Marketing. In her new role, Mandy will lead commercial activities across the UK and

Eleticia Szozda

Ciliatech are delighted to announce the appointment of Eleticia (“Ele”) Szozda as Global Surgical Training Consultant, joining the company to strengthen its global surgical education programme and support the commercialisation of the Intercil® Uveal Spacer, while reporting directly to Sahil Syed, VP Sales & Marketing. In her new role, Ele

Intercil is a surgically implantable medical device that is indicated in adult patients (18 years old and older) suffering from mild to moderate glaucoma. Intercil is intended for use only by trained ophthalmic surgeons. The device is not exempt from the usual risks of surgery.

This site is only for the use of professionals associated with the field of Ophthalmology and is not intended for patients.